The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Abstract
After it was discovered approximately 40 years ago, carbohydrate antigen 125 (CA125) became the most widely used and concerning biomarker in ovarian cancer screening. However, there is still controversy about its role in clinical practice. CA125 is not sufficiently reliable in diagnosis to screen for early-stage ovarian cancer. On the other hand, CA125 has been a valuable indicator for evaluating chemotherapeutic efficacy and prognosis. We still do not know much about its biological role, and several studies have indicated that this marker participates in the occurrence and development of ovarian cancer. Currently, an increasing number of scholars have begun to pay attention to CA125-targeted treatment strategies. In the interest of better design and development of anticancer therapies, a renewed and systematic understanding of the roles of CA125 in diagnosis, prediction, and tumorigenesis is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 643
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Gubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Ovarian Cancer: A Heterogeneous Disease
Kossaï, M., Leary, A., Scoazec, J.-Y., & Genestie, C. (2018) · Pathobiology · doi:10.1159/000479006 · Cited by 388
Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018) · JAMA · doi:10.1001/jama.2017.21421 · Cited by 348
Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., & Skates, S. J. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318224fce2 · Cited by 308
Koneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0460-x · Cited by 302
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
O’Brien, T. J., Beard, J. B., Underwood, L. J., Dennis, R. A., Santin, A. D., & York, L. (2001) · Tumor Biology · doi:10.1159/000050638 · Cited by 300
Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene
Yin, B. W. T., Dnistrian, A., & Lloyd, K. O. (2002) · International Journal of Cancer · doi:10.1002/ijc.10250 · Cited by 239
Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors
Ueland, F. R., Desimone, C. P., Seamon, L. G., Miller, R. A., Goodrich, S., Podzielinski, I., Sokoll, L., Smith, A., van Nagell, J. R., & Zhang, Z. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31821b5118 · Cited by 231
Hamd-Ghadareh, S., Salimi, A., Fathi, F., & Bahrami, S. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.05.003 · Cited by 214
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A., Felder, M., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 209
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Belisle, J. A., Horibata, S., Jennifer, G. A., Petrie, S., Kapur, A., André, S., Gabius, H.-J., Rancourt, C., Connor, J., Paulson, J. C., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-118 · Cited by 207
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J., Rivkin, S., Schultes, B. C., Whiteside, T. L., & Nicodemus, C. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.016 · Cited by 191
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
Thériault, C., Pinard, M., Comamala, M., Migneault, M., Beaudin, J., Matte, I., Boivin, M., Piché, A., & Rancourt, C. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.020 · Cited by 189
Chekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 171
The cancer antigen CA125 represents a novel counter receptor for galectin-1
Seelenmeyer, C., Wegehingel, S., Lechner, J., & Nickel, W. (2003) · Journal of Cell Science · doi:10.1242/jcs.00312 · Cited by 153
Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer
Cooper, B. C., Sood, A., Davis, C. S., Ritchie, J., Sorosky, J., Anderson, B., & Buller, R. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02057-4 · Cited by 151
Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses
Coleman, R. L., Herzog, T. J., Chan, D. W., Munroe, D. G., Pappas, T. C., Smith, A., Zhang, Z., & Wolf, J. K. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.03.003 · Cited by 151
Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review
van Baal, J. O. A. M., Noorden, C. J. F. V., Nieuwland, R., de Vijver, K. K. V., Sturk, A., van Driel, W. J., Kenter, G. G., & Lok, C. A. R. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417742897 · Cited by 151
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
Patankar, M. S., JING, Y., Morrison, J. G., Belisle, J. A., Lattanzio, F. A., DENG, Y., Wong, N. K., MORRIS, H., Dell, A., & CLARK, G. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.07.030 · Cited by 149
Sabbatini, P. J., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K., Kurzeder, C., Schmalfeldt, B., Cibula, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4057 · Cited by 145
Brien, T. J. O. R., Beard, J. B., Underwood, L. J., & Shigemasa, K. (2002) · Tumor Biology · doi:10.1159/000064032 · Cited by 141
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
Crawford, A., Haber, L., Kelly, M. P., Vazzana, K., Canova, L., Ram, P., Pawashe, A., Finney, J., Jalal, S., Chiu, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7534 · Cited by 135
Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125
Reinartz, S., Köhler, S., Schlebusch, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0056 · Cited by 134
Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer
Chen, K., Gentry‐Maharaj, A., Burnell, M., Steentoft, C., Marcos-Silva, L., Mandel, U., Jacobs, I. J., Dawnay, A., Menon, U., & Blixt, O. (2013) · Journal of Proteome Research · doi:10.1021/pr3010474 · Cited by 112
Comamala, M., Pinard, M., Thériault, C., Matte, I., Albert, A., Boivin, M., Beaudin, J., Piché, A., & Rancourt, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.34 · Cited by 111
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy
Das, S., & Batra, S. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1050 · Cited by 111
Belisle, J. A., Gubbels, J. A. A., Raphael, C. A., Migneault, M., Rancourt, C., Connor, J. P., & Patankar, M. S. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02660.x · Cited by 110
Noujaim, A. A., Schultes, B. C., Baum, R. P., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780152389384 · Cited by 110
Carew, J. S., Nawrocki, S. T., Krupnik, Y. V., Dunner, K., McConkey, D. J., Keating, M. J., & Huang, P. (2005) · Blood · doi:10.1182/blood-2005-05-1923 · Cited by 109
Diverse functions of p120ctn in tumors
van Hengel, J., & Roy, F. M. V. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.08.033 · Cited by 92
Exploring the Glycosylation of Serum CA125
Saldova, R., Struwe, W. B., Wynne, K. J., Elia, G., Duffy, M. J., & Rudd, P. M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815636 · Cited by 90
Serum Glycome Profiling: A Biomarker for Diagnosis of Ovarian Cancer
Biskup, K., Braicu, E. I., Sehouli, J., Fotopoulou, C., Tauber, R., Berger, M., & Blanchard, V. (2013) · Journal of Proteome Research · doi:10.1021/pr400405x · Cited by 87
Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?
Gadducci, A., Fuso, L., Cosio, S., Landoni, F., Maggino, T., Perotto, S., Sartori, E., Testa, A. C., Galletto, L., & Zola, P. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a1cc02 · Cited by 84
IGF system targeted therapy: Therapeutic opportunities for ovarian cancer
Visser, J. A. L., Meijering, R. A. M., Reyners, A. K. L., van der Zee, A. G. J., & de Jong, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.012 · Cited by 76
Baert, T., Camp, J. V., Vanbrabant, L., Busschaert, P., Laenen, A., Han, S., Nieuwenhuysen, E. V., Vergote, I. B., & Coosemans, A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.004 · Cited by 71
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
Tuxen, M. K., Sölétormos, G., & Dombernowsky, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1787 · Cited by 68
Morgado, M., Sutton, M. N., Simmons, M., Warren, C. R., Lü, Z., Constantinou, P. E., Liu, J., Francis, L. W., Conlan, R. S., Bast, R. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7652 · Cited by 68
Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma
Qin, L. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0111-1 · Cited by 66
Fan, K., Yang, C., Fan, Z., Huang, Q., Zhang, Y., Cheng, H., Jin, K., Yu, L., Wang, Z., Luo, G., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.017 · Cited by 66
Möbus, V. J., Baum, R. P., Bolle, M., et al. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.347 · Cited by 65
Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer
Akinwunmi, B. O., Babić, A., Vitonis, A. F., Cramer, D. W., Titus, L. J., Tworoger, S. S., & Terry, K. L. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0203 · Cited by 62
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0296 · Cited by 59
Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifyingGolgi/post-Golgi compartments
Das, S., Majhi, P. D., Al‐Mugotir, M., Rachagani, S., Sorgen, P. L., & Batra, S. K. (2015) · Scientific Reports · doi:10.1038/srep09759 · Cited by 56
Terlikowska, K. M., Dobrzycka, B., Witkowska, A. M., et al. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0254-7 · Cited by 50
Akita, K., Minami, T., Tanida, S., Mori, Y., Toda, M., & Nakada, H. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.10.005 · Cited by 48
Chen, X., Li, X., Wang, X., Zhu, Q., Wu, X., & Wang, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5371-4 · Cited by 46
Matte, I., Garde‐Granger, P., Bessette, P., & Piché, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5611-7 · Cited by 44
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth
Rao, T. D., Fernández‐Tejada, A., Axelrod, A. J., Rosales, N., Yan, X., Thapi, S., Wang, A., Park, K. J., Nemieboka, B. E., Xiang, J., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00305 · Cited by 41
Lindemann, K. Y., Kristensen, G. B., Mirza, M. R., Davies, L. C., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M. J., Raspagliesi, F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw238 · Cited by 40
Matte, I., Lane, D. A., Boivin, M., Rancourt, C., & Piché, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-234 · Cited by 34
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
Xiang, X. M., Feng, M., Felder, M. A. R., Connor, J. P., Man, Y., Patankar, M. S., & Ho, M. (2011) · Journal of Cancer · doi:10.7150/jca.2.280 · Cited by 34
Kline, J. B., Kennedy, R., Albone, E. F., Chao, Q., Fernando, S., McDonough, J., Rybinski, K. A., Wang, W., Somers, E. B., Schweizer, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19090 · Cited by 32
Xiong, L., Woodward, A. M., & Argüeso, P. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7196 · Cited by 27
p120catenin alteration in cancer and its role in tumour invasion
Péglion, F., & Etienne‐Manneville, S. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0015 · Cited by 26
Buzzonetti, A., Fossati, M., Catzola, V., Scambia, G., Fattorossi, A., & Battaglia, A. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1569-0 · Cited by 25
Gidwani, K., Nadeem, N., Huhtinen, K., Kekki, H., Heinosalo, T., Hynninen, J., Perheentupa, A. H., POUTANEN, M. H., Carpén, O., Pettersson, K. S. I., et al. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.028266 · Cited by 24
Battaglia, A., Fossati, M., Buzzonetti, A., Scambia, G., & Fattorossi, A. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.09.006 · Cited by 22
Wang, W., Somers, E. B., Ross, E. N., Kline, J. B., O'Shannessy, D. J., Schweizer, C., Weil, S. C., Grasso, L., & Nicolaides, N. C. (2017) · Cytogenetic and Genome Research · doi:10.1159/000481213 · Cited by 22
Fawzy, A., Mohamed, M. R., Ali, M. A. M., El-Magied, M. H. A., & Helal, A. M. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.1.323 · Cited by 21
Sasaki, A., Akita, K., Ito, F., Mori, T., Kitawaki, J., & Nakada, H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29185 · Cited by 19
Nicolaides, N. C., Schweizer, C., Somers, E. B., Wang, W., Fernando, S., Ross, E. N., Grasso, L., Hassan, R., & Kline, J. B. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449614 · Cited by 17
Zhang, M.-X., Hong, S., Cai, Q., Zhang, M., Chen, J., Zhang, X., & Xu, C. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1451934 · Cited by 12
Self-citationAnti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort
Cramer, D. W., Fichorova, R. N., Terry, K. L., Yamamoto, H. S., Vitonis, A. F., Ardanáz, E., Aune, D., Boeing, H., Brändstedt, J., Boutron‐Ruault, M., et al. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0744 · Cited by 9
Tumor‐shed antigen CA125 blocks complement‐mediated killing via suppression of C1q‐antibody binding
Kline, J. B., Fernando, S., Ross, E. N., Grasso, L., & Nicolaides, N. C. (2018) · European Journal of Immunology · doi:10.1002/eji.201847707 · Cited by 9
He, Y., Gu, Z., Zhu, Q., Chen, M., He, C., Huang, Y., Li, Q., & Di, W. J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32237 · Cited by 3
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Self-citation
Metadata
- Authors
- Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 1875
- Issue
- 2
- Pages
- 188503
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3121118670
- Cited by
- 384
- References
- 78
- FWCI
- 39.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.